PMID- 23286853
OWN - NLM
STAT- MEDLINE
DCOM- 20130614
LR  - 20181202
IS  - 1478-3231 (Electronic)
IS  - 1478-3223 (Linking)
VI  - 33 Suppl 1
DP  - 2013 Feb
TI  - Patients with HCV and F1 and F2 fibrosis stage: treat now or wait?
PG  - 105-10
LID - 10.1111/liv.12066 [doi]
AB  - The current standard of care (SOC) for patients with chronic HCV genotype 1 is a 
      combination of either boceprevir or telaprevir with peginterferon (PEG-IFN) and 
      ribavirin (RBV). Although it is effective in a high percentage of patients, this 
      treatment is associated with significant adverse events (AEs). The next 
      generation of protease inhibitors, simeprevir and faldaprevir, will also be used 
      with PEG-IFN/RBV. Interferon-free therapy with sofosbuvir appears promising and 
      on the horizon for patients with genotypes 2 and 3, but may still be many years 
      away for patients with HCV genotype 1. The factors which should be considered 
      when deciding whether to treat a patient with HCV and mild fibrosis with the 
      current SOC now, or to delay treatment until less toxic and/or more effective 
      therapy is available is discussed.
CI  - (c) 2012 John Wiley & Sons A/S.
FAU - Shiffman, Mitchell L
AU  - Shiffman ML
AD  - Liver Institute of Virginia, Bon Secours Health System, Richmond and Newport 
      News, VA 23226, USA. Mitchell_shiffman@bshsi.org
FAU - Benhamou, Yves
AU  - Benhamou Y
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Liver Int
JT  - Liver international : official journal of the International Association for the 
      Study of the Liver
JID - 101160857
RN  - 0 (Antiviral Agents)
RN  - 0 (Interferon alpha-2)
RN  - 0 (Interferon-alpha)
RN  - 0 (Recombinant Proteins)
RN  - 0 (Serine Proteinase Inhibitors)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - 49717AWG6K (Ribavirin)
RN  - G8RGG88B68 (peginterferon alfa-2b)
RN  - Q46947FE7K (peginterferon alfa-2a)
SB  - IM
MH  - Antiviral Agents/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Genotype
MH  - Hepacivirus/*drug effects/enzymology/genetics
MH  - Hepatitis C/complications/diagnosis/*drug therapy
MH  - Humans
MH  - Interferon alpha-2
MH  - Interferon-alpha/therapeutic use
MH  - Liver Cirrhosis/pathology/*virology
MH  - Patient Selection
MH  - Phenotype
MH  - Polyethylene Glycols/therapeutic use
MH  - Predictive Value of Tests
MH  - Recombinant Proteins/therapeutic use
MH  - Ribavirin/therapeutic use
MH  - Serine Proteinase Inhibitors/adverse effects/*therapeutic use
MH  - Severity of Illness Index
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2013/01/11 06:00
MHDA- 2013/06/15 06:00
CRDT- 2013/01/05 06:00
PHST- 2013/01/05 06:00 [entrez]
PHST- 2013/01/11 06:00 [pubmed]
PHST- 2013/06/15 06:00 [medline]
AID - 10.1111/liv.12066 [doi]
PST - ppublish
SO  - Liver Int. 2013 Feb;33 Suppl 1:105-10. doi: 10.1111/liv.12066.